InflaRx stock: buy or sell?
December 6th, 2019
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States.
Should I buy InflaRx stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with InflaRx stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is InflaRx stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 7 ratings published for IFRX stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-5||Raymond James||Outperform||Market Perform|
|2019-6-5||JPMorgan Chase & Co.||Overweight||Underweight|
|2019-6-5||Credit Suisse Group||Outperform||Underperform|
|2019-3-29||Robert W. Baird||Outperform||Outperform|
|2019-2-5||JPMorgan Chase & Co.||Overweight||Top Pick|
InflaRx stock analysis
InflaRx shares fell -3.07% to $3.16 on December/6.
InflaRx shares fell -3.07% to $3.16 on Dec 6th. For the last 12 days when IFRX stock price broke up the SMA100d line, it gained $0.51 (19.25%).
After boosting an extraordinary 23.24% in a week last week, InflaRx closed this week at $3.16 and collapsed a spooky -7.06%.
In a weekly time frame, InflaRx stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, IFRX might consolidate in a flat-base, waiting to break out over or down under . Since early June, when IFRX stock price broke down the 40-weeks moving avarage line, it slid $-32.83 per share (-91.22%). Stocks under the 40-weeks moving average line are usually not recommended for average traders. Far behind is the all-time high InflaRx recorded late April and since then the price is -94.05% below that top.
InflaRx stock price history
InflaRx IPO was on November 8th, 2017 at $15.19 per share1. Since then, IFRX stock declined a -79.20%, with a yearly average of -39.60%.
1: Adjusted price after possible price splits or reverse-splits.
InflaRx stock historical price chart
IFRX stock reached all-time highs on April with a price of $53.10.
InflaRx stock price target is $34.30Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 4 price targets for IFRX stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-5||JPMorgan Chase & Co.||Downgrades||$67.00||$9.00||-86.6%|
|2019-3-29||Robert W. Baird||Lowers Target||$62.00||$58.00||-6.5%|
|2019-2-5||JPMorgan Chase & Co.||Reiterates||$42.00||$65.00||54.8%|
Financials and fundamental analysis
Earnings date and Earnings per ShareInflaRx presented slightly fine results for 2018-Q4 on March. InflaRx grew Earnings per Share (EPS) by 4.50%, beating experts estimates of $-0.44. InflaRx posted $-0.46.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual sales report draw of to M dollars. , its profit margin (compared to sales) to , that is million.
Quarterly financial resultsReported quarter income marked $-10.28 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, InflaRx sales marked a tight move and remained constant a nan%. Looking back to recent quarterly results, InflaRx posted 7 negative quarters in a row.
InflaRx ownershipWhen you are planning to invest in shares of a stock, it's worth to check its ownership structure.
InflaRx shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 38.72% of all shares.
In case of InflaRx stock, 60.93% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for IFRX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to InflaRx:
|Market cap||$82.5 M||$336.9 M||$188.0 M|
|Total shares||26.1 M||114.2 M||55.0 M|
|Float shares||16.2 M||96.5 M||41.5 M|
|- Institutional holdings (%)||60.9%||95.2%||72.8%|
|- Insider holdings (%)||38.7%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$3.04 - $3.29|
|Average true range||$0.29|
|50d mov avg||$2.61|
|100d mov avg||$2.72|
|200d mov avg||$16.78|
InflaRx performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared InflaRx against PDL BioPharma and Pieris Pharmaceuticals in the following table: